Form 4: Sarepta Therapeutics Executive Cristin Rothfuss Reports Stock and Option Grants

Sarepta Therapeutics' EVP, General Counsel, Cristin Rothfuss, received 2,000 restricted stock units and options to purchase 4,000 shares of common stock.

Summary

• Cristin Rothfuss, EVP and General Counsel at Sarepta Therapeutics, reported a transaction involving the acquisition of company securities.
• On November 26, 2024, Ms. Rothfuss was granted 2,000 restricted stock units (RSUs).
• Each RSU represents the right to receive one share of Sarepta Therapeutics common stock.
• The RSUs vest over four years, with 25% vesting on the first anniversary of the grant date and an additional 25% vesting each year thereafter.
• Ms. Rothfuss also received options to purchase 4,000 shares of common stock at an exercise price of $130.50.
• The options vest over four years, with the first 25% vesting on November 26, 2025, and 1/48th of the total granted option vesting monthly thereafter.
• Following these transactions, Ms. Rothfuss directly owns 13,817 shares of common stock and options to purchase 4,000 shares.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, which is generally viewed positively as it aligns management interests with shareholders. There are no negative implications.

Positives

• The grant of RSUs and stock options to a key executive like Cristin Rothfuss aligns her interests with those of the shareholders.
• The vesting schedule of the RSUs and options encourages long-term commitment from the executive.

Future Outlook

The vesting schedule of the RSUs and options suggests a long-term commitment from the executive.

Industry Context

This type of equity-based compensation is common practice for publicly traded companies to incentivize and retain key executives.

Comparison to Industry Standards

• Equity grants, including RSUs and stock options, are a standard component of executive compensation packages in the biotechnology industry.
• Companies like BioMarin Pharmaceutical and Vertex Pharmaceuticals also use similar equity-based incentives to align executive interests with shareholder value.
• The vesting schedules described are typical for these types of grants, encouraging long-term performance and retention.

Stakeholder Impact

• The grant of equity to a key executive can be viewed positively by shareholders as it aligns management's interests with the company's long-term success.
• Employees may see this as a positive sign of the company's commitment to its leadership.

Key Dates

Keywords

Sarepta Therapeutics, stock options, restricted stock units, executive compensation, insider trading, Form 4, SRPT, vesting